Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.

Status Not yet recruiting
Results Published
Start date 15 January 2022
End date 31 December 2023
Chance of happening 88%
Phase Phase I Phase II
Design Open
Type Interventional
Generation First
Participants 30
Sex All
Age 18- 99
Therapy No

Trial Details

The trial will take place with individuals admitted to a residential rehabilitation treatment program. The treatment protocol will consist of 4 preparatory therapy visits, 2 psilocybin sessions (25-30mg), and 8 total integration therapy visits. Primary aims assess acceptability, feasibility, and safety with a primary endpoint at the conclusion of the study intervention. An additional aim assesses preliminary efficacy for methamphetamine use disorder and overall functioning at follow-up assessments 60 and 180 days after discharge from the residential treatment program.

NCT Number NCT04982796

Sponsors & Collaborators

Oregon Health & Science University
Psychedelic research is underway at the Oregon Health and Science University. It is likely more research will emerge given the state recently legalized psilocybin.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.